Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
US4525EP1011
Thu, 20.02.2025
Immunic AG
Immunic’s Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
– New Data Suggests that IMU-856 Could Be a Potential Oral Treatment Option for Weight Management; Program Is Phase 2 Ready –
– Dose-Dependent Increase of Endogenous GLP-1 Levels Observed in Post Hoc A [ … ]
Tue, 04.02.2025
Immunic AG
Immunic to Participate in Investor and Scientific Conferences in February
NEW YORK, February 4, 2025 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and s [ … ]
Tue, 07.01.2025
Immunic AG
Immunic Highlights 2024 Accomplishments and Upcoming Milestones
– Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April –
– Reported Positive Outcome from Interim Analysis of Ongoing, Twin Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Both Trials on [ … ]